Lawrence Blonde

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7416560/publications.pdf

Version: 2024-02-01

95 papers	7,995 citations	147801 31 h-index	48315 88 g-index
98 all docs	98 docs citations	98 times ranked	7533 citing authors

#	Article	IF	Citations
1	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, The, 2009, 374, 39-47.	13.7	1,324
2	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care, 2009, 32, 1224-1230.	8.6	768
3	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015. Endocrine Practice, 2015, 21, 1-87.	2.1	443
4	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy, 2018, 35, 1763-1774.	2.9	424
5	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	2.1	410
6	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm â€“ 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	2.1	405
7	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	2.1	388
8	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice, 2011, 17, 1-53.	2.1	387
9	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm â€“ 2017 Executive Summary. Endocrine Practice, 2017, 23, 207-238.	2.1	362
10	American Association of Clinical Endocrinologists and American College of Endocrinology â€“ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015 â€” Executive Summary. Endocrine Practice, 2015, 21, 413-437.	2.1	359
11	Aace Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice, 2013, 19, 327-336.	2.1	318
12	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2019 Executive Summary. Endocrine Practice, 2019, 25, 69-101.	2.1	245
13	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet, The, 2015, 385, 2057-2066.	13.7	180
14	Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. American Journal of Clinical Nutrition, 2000, 71, 1433-1438.	4.7	141
15	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58, 1183-1187.	6.3	118
16	Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 2004, 20, 565-572.	1.9	111
17	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology, 2017, 16, 6.	6.8	107
18	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 172-183.	2.0	102

#	Article	IF	Citations
19	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy, 2006, 4, 871-895.	1.5	89
20	Current evidence regarding the value of self-monitored blood glucose testing. American Journal of Medicine, 2005, 118, 20-26.	1.5	74
21	Realâ€world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes, Obesity and Metabolism, 2018, 20, 1293-1297.	4.4	63
22	Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 12.	6.8	62
23	Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2010, 123, S12-S18.	1.5	59
24	Clinical outcomes in realâ€world patients with type 2 diabetes switching from firstâ€to secondâ€generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 2148-2158.	4.4	59
25	Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Advances in Therapy, 2012, 29, 1-13.	2.9	55
26	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine, 2016, 128, 371-380.	2.0	55
27	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care, 2019, 42, 2108-2116.	8.6	50
28	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy, 2018, 9, 1347-1358.	2.5	47
29	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 438-444.	2.3	43
30	Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus. American Journal of the Medical Sciences, 2012, 343, 17-20.	1.1	37
31	Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine, 2009, 76, S4-S11.	1.3	33
32	Current challenges in diabetes management. Clinical Cornerstone, 2005, 7, S6-S17.	0.7	32
33	Identifying Risk Factors for Severe Hypoglycemia in Hospitalized Patients with Diabetes. Endocrine Practice, 2014, 20, 1051-1056.	2.1	29
34	Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2015, 2015, 1-13.	2.3	29
35	Liraglutide as addâ€on to sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRAâ€ADD2SGLT2i, a 26â€week, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 929-937.	4.4	29
36	Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials*. Current Medical Research and Opinion, 2006, 22, 2111-2120.	1.9	27

#	Article	IF	Citations
37	Switching to insulin glargine 300 units/mL in realâ€world older patients with type 2 diabetes (DELIVER 3). Diabetes, Obesity and Metabolism, 2019, 21, 2384-2393.	4.4	25
38	Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Realâ€world results from the DELIVER NaÃ¯ve cohort study. Diabetes, Obesity and Metabolism, 2019, 21, 1596-1605.	4.4	25
39	Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. Diabetes Spectrum, 2020, 33, 8-15.	1.0	25
40	New concepts in diabetes: how multihormonal regulation can improve glycemic control. Journal of Managed Care Pharmacy, 2004, 10, S3-8; quiz S9, S11-2.	2.2	24
41	Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice, 2014, 20, 1322-1332.	2.1	23
42	Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Current Medical Research and Opinion, 2019, 35, 793-804.	1.9	22
43	Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin. Diabetes Therapy, 2018, 9, 1169-1184.	2.5	18
44	Getting to the â€œHeartâ€•of the Matter on Diabetic Cardiovascular Disease: â€œThanks for the Memoryâ€• Diabetes Care, 2016, 39, 664-667.	8.6	17
45	Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. Diabetes Spectrum, 2019, 32, 93-103.	1.0	15
46	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in Therapy, 2018, 35, 939-965.	2.9	14
47	Insulin glargine/lixisenatide fixedâ€ratio combination (<scp>iGlarLixi</scp>) compared with premix or addition of mealâ€time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 2179-2188.	4.4	14
48	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes Therapy, 2020, 11, 2629-2645.	2.5	14
49	Internet Resources to Improve Health Care for Patients with Diabetes. Endocrine Practice, 2006, 12, 131-137.	2.1	13
50	Lixisenatide as addâ€on treatment among patients with different Î²â€cell function levels as assessed by HOMAâ€Î²² index. Diabetes/Metabolism Research and Reviews, 2017, 33, e2897.	4.0	13
51	Predictors of outcomes in patients with type 2 diabetes in the lixisenatide <scp>GetGoal</scp> clinical trials. Diabetes, Obesity and Metabolism, 2017, 19, 275-283.	4.4	13
52	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 979-994.	5.7	13
53	Longâ€term sustainability of glycaemic achievements with secondâ€line antidiabetic therapies in patients with type 2 diabetes: <scp>A</scp> realâ€world study. Diabetes, Obesity and Metabolism, 2018, 20, 1722-1731.	4.4	12
54	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation, 2016, 36, 293-303.	2.2	11

#	Article	IF	Citations
55	Efficacy and safety of <scp>iGlarLixi</scp> versus <scp>IDegLira</scp> in adults with type 2 diabetes inadequately controlled by glucagonâ€like peptideâ€1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes, Obesity and Metabolism, 2020, 22, 2170-2178.	4.4	11
56	DEFINING AND MEASURING QUALITY OF DIABETES CARE. Primary Care - Clinics in Office Practice, 1999, 26, 841-855.	1.6	10
57	Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clinical Therapeutics, 2015, 37, 1045-1054.	2.5	10
58	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 1993-2000.	1.9	10
59	A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Current Medical Research and Opinion, 2018, 34, 1143-1152.	1.9	10
60	Insulin glargine 300â€‰U/ mL versus firstâ€generation basal insulin analogues in insulinâ€naÃ¯ve adults with type 2 diabetes: 12â€month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic realâ€life clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 1995-2003.	4.4	10
61	Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study. JMIR Diabetes, 2021, 6, e24687.	1.9	10
62	State of diabetes care in the United States. American Journal of Managed Care, 2007, 13 Suppl 2, S36-40.	1.1	10
63	Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners, 2006, 18, 524-533.	1.4	9
64	Impact of disease duration and Î²â€cell reserve on the efficacy of switching to <scp>iGlarLixi</scp> in adults with type 2 diabetes on glucagonâ€like peptideâ€1 receptor agonist therapy: Exploratory analyses from the <scp>LixiLanâ€G</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1567-1576.	4.4	9
65	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate Medicine, 2020, 132, 15-25.	2.0	8
66	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care, 2021, 44, 8-10.	8.6	8
67	Diabetes Care: â€œTaking It to the Limit One More Timeâ€. Diabetes Care, 2017, 40, 3-6.	8.6	7
68	A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research, 2016, 16, 356.	2.2	6
69	Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. Diabetes Research and Clinical Practice, 2017, 133, 150-158.	2.8	6
70	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. Advances in Therapy, 2021, 38, 1715-1731.	2.9	6
71	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes Care, 2021, 44, 774-780.	8.6	6
72	Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors. Postgraduate Medicine, 2014, 126, 172-189.	2.0	5

#	Article	IF	Citations
73	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, Obesity and Metabolism, 2018, 20, 921-929.	4.4	5
74	Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L. Diabetes Therapy, 2020, 11, 1007-1015.	2.5	5
75	Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Advances in Therapy, 2021, 38, 594-606.	2.9	5
76	Insulin glargine 300â€‰units/<scp>mL</scp> for the treatment of individuals with type 2 diabetes in the real world: A review of the <scp>DELIVER</scp> programme. Diabetes, Obesity and Metabolism, 2021, 23, 1713-1721.	4.4	5
77	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. Diabetes Therapy, 2022, 13, 205-215.	2.5	5
78	What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?. Journal of Managed Care Pharmacy, 2006, 12, 1-16.	2.2	4
79	The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. Current Medical Research and Opinion, 2018, 34, 1501-1511.	1.9	4
80	Big Topics forDiabetes Carein 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care, 2018, 41, 1327-1329.	8.6	4
81	Improving care for patients with type 2 diabetes: applying management guidelines and algorithms, and a review of new evidence for incretin agents and lifestyle intervention. American Journal of Managed Care, 2011, 17 Suppl 14, S368-76.	1.1	3
82	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in Therapy, 2019, 36, 2310-2326.	2.9	2
83	Switching to <scp>iGlarLixi</scp> versus continuation of a daily or weekly glucagonâ€like peptideâ€1 receptor agonist (<scp>GLP</scp>â€1 <scp>RA</scp>) in insufficiently controlled type 2 diabetes: A <scp>LixiLanâ€G</scp> trial subgroup analysis by HbA1c and <scp>GLP</scp>â€1 <scp>RA</scp> use at screening. Diabetes, Obesity and Metabolism, 2021, 23, 1331-1341.	4.4	2
84	Efficacy of liraglutide added to sodiumâ€glucose cotransporterâ€2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Postâ€hoc analysis of <scp>LIRAâ€ADD2SGLT2i</scp>. Diabetes, Obesity and Metabolism, 2021, 23, 2234-2241.	4.4	2
85	Achieving antihyperglycemic treatment goals with incretin-related therapies. American Journal of Managed Care, 2012, 18, S219-27.	1.1	2
86	Patient management strategies in type 2 diabetes: current practices and future considerations. Journal of Managed Care Pharmacy, 2005, 11, S12-8.	2.2	2
87	From Randomized Controlled Trials to the Real World: Putting Evidence into Context. Journal of Family Practice, 2018, 67, S55-S60.	0.2	2
88	Real-world evidence in diabetes: relevance to clinical practice. Journal of Family Practice, 2019, 68, .	0.2	2
89	Easing the Transition to Insulin Therapy in People With Type 2 Diabetes. The Diabetes Educator, 2007, 33, 232S-240S.	2.5	1
90	Diabetes Care: â€œLagniappeâ€•and â€œSeeing Is Believingâ€!. Diabetes Care, 2016, 39, 1069-1071.	8.6	1

#	Article	IF	Citations
91	Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice, 2018, 24, 8-19.	2.1	1
92	Adherence to Practice Guidelines for People with Diabetes Mellitus. , 2008, , 235-249.		1
93	Case Presentation. The Diabetes Educator, 2007, 33, 114S-116S.	2.5	0
94	OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the Endocrine Society, 2019, 3, .	0.2	0
95	Editorial Cycles and Continuity of Diabetes Care. Diabetes Care, 2022, 45, 1493-1494.	8.6	0